However, I stand by my call for some, of not all of the BOD, to be culled and fresh blood brought in.. I want to be reading about this product and seeing stuff in journals about it. Publicity and sales makes companies, not wheeling and dealing behind closed doors...
The only thing about this now is that it has become a long term hold, and it will almost certainly fall further as we approach cash shortages... The majority of the value of my holding as well as most of the others on here is gone for now, but our one iron in the fire is the product itself... I would say to MF, you have no choice but to hold now, some have a choice to take what they can but either way it will be painful. As has been pointed out, the BOD still own a chunk of this and some of their averages may be higher. I think they've done a shocking job in wasting the early days of this product by not Singing its praises everywhere in all the specialist newsletters and journals... I think the IP is worth good money and the EU hasn't finished adding red tape to pharma testing yet... So it would seems for those of us who have lost the most so far, hold we must... The product may yet be somebody's answer to their prayers...
It is so sad to witness what is happening here. EVO investor relations is non-existent and has been for a very long time. I sincerely hope that for those still invested here that this can somehow get back near to 1.5-2.0p. But I fear it may get worse before it gets better.
Im in agreement that Labskin has huge potential, but now i suppose there are questions that need to be addressed. Is it too sophisticated for the purpose its designed for? can costs be brought down to fall in line with competitors ? is the fact that its not validated an issue?
All these points aside, it would be quite a nice purchase for a large multinational to keep in their back pocket for the future.
I really don't know what to make of all this... Ive been stuck for words recently that why my posting has slowed down quite considerably. Poor MF.... Group hug everybody
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.